Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulonivirine (MK-8507) PK with Atorvastatin and Metformin in Healthy Adults
NCT07530289Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ulonivirine in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoint: Area Under the Concentration-Time Curve From Time 0 to Infinity. Started Apr 2026; status: completed.
02
Drugs
ulonivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07530289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07530289.